Table 1.
Patients categorized from target tissue
| Categories | Tissue source (patient number, n) | Age (year, mean ± SD) | Most advanced pathological diagnosis (patient number, n) | |
|---|---|---|---|---|
| 1 | Reduction mammoplasty (24) | 38.3 ± 10.9 | Normal (24) | |
| 2 | Non-proliferative benign lesions (14) | 44.4 ± 15.9 | Fibrocystic changes (2) | |
| Fibroadenoma (9) | ||||
| Apocrine metaplasia (3) | ||||
| 3 | Proliferative lesions without atypia (10) | 49.5 ± 13.8 | Intraductal papilloma (3) | |
| Ductal epithelial hyperplasia (5) | ||||
| Sclerosing adenosis (2) | ||||
| 4 | Proliferative lesions with atypia (15) | 53.7 ± 11.9 | Atypical ductal hyperplasia (10) | |
| Atypical lobular hyperplasia (5) | ||||
| 5 | ‘‘Malignant-adjacent’’ normal (32) | 60.1 ± 14.5 | Malignant (32) | |
| Stage I (16) | ER-positive (26) | |||
| Stage II (10) | PR-positive (23) | |||
| Stage III (2) | HER2-positive (3) | |||
| No staging data (4) | ||||
| 6 | Invasive carcinoma (59) | 60.7 ± 12.2 | Malignant (59) | |
| Stage I (24) | ER-positive (50) | |||
| Stage II (15) | PR-positive (46) | |||
| Stage III (15) | HER2-positive (6) | |||
| Stage IV (1) | ||||
| No staging data (4) | ||||